Northeast Financial Consultants’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.13M | Hold |
16,867
| – | – | 0.13% | 86 |
|
|
2025
Q1 | $3.53M | Hold |
16,867
| – | – | 0.16% | 76 |
|
|
2024
Q4 | $3M | Hold |
16,867
| – | – | 0.13% | 87 |
|
|
2024
Q3 | $3.33M | Buy |
16,867
+37
| +0.2% | +$6.91K | 0.15% | 81 |
|
|
2024
Q2 | $2.89M | Sell |
16,830
-700
| -4% | -$116K | 0.13% | 86 |
|
|
2024
Q1 | $3.19M | Buy |
17,530
+1,183
| +7% | +$204K | 0.16% | 86 |
|
|
2023
Q4 | $2.53M | Hold |
16,347
| – | – | 0.14% | 93 |
|
|
2023
Q3 | $2.44M | Sell |
16,347
-2,156
| -12% | -$317K | 0.15% | 95 |
|
|
2023
Q2 | $2.49M | Buy |
18,503
+22
| +0.1% | +$3.23K | 0.15% | 91 |
|
|
2023
Q1 | $2.95M | Sell |
18,481
-1,745
| -9% | -$267K | 0.19% | 81 |
|
|
2022
Q4 | $3.27M | Buy |
20,226
+1,895
| +10% | +$291K | 0.22% | 72 |
|
|
2022
Q3 | $2.46M | Buy |
18,331
+830
| +5% | +$119K | 0.18% | 80 |
|
|
2022
Q2 | $2.68M | Sell |
17,501
-572
| -3% | -$87.4K | 0.19% | 80 |
|
|
2022
Q1 | $2.93M | Buy |
18,073
+302
| +2% | +$43.9K | 0.17% | 84 |
|
|
2021
Q4 | $2.41M | Sell |
17,771
-1,326
| -7% | -$157K | 0.15% | 80 |
|
|
2021
Q3 | $2.06M | Buy |
19,097
+227
| +1% | +$25.9K | 0.14% | 93 |
|
|
2021
Q2 | $2.13M | Sell |
18,870
-62
| -0.3% | -$6.98K | 0.14% | 92 |
|
|
2021
Q1 | $2.05M | Buy |
18,932
+209
| +1% | +$22.4K | 0.16% | 86 |
|
|
2020
Q4 | $2.01M | Hold |
18,723
| – | – | 0.17% | 82 |
|
|
2020
Q3 | $1.64M | Buy |
18,723
+481
| +3% | +$45.3K | 0.15% | 87 |
|
|
2020
Q2 | $1.79M | Buy |
18,242
+6,744
| +59% | +$594K | 0.17% | 77 |
|
|
2020
Q1 | $876K | Buy |
11,498
+10
| +0.1% | +$852 | 0.1% | 129 |
|
|
2019
Q4 | $1.02M | Buy |
11,488
+576
| +5% | +$47.8K | 0.09% | 134 |
|
|
2019
Q3 | $826K | Buy |
10,912
+136
| +1% | +$9.32K | 0.08% | 144 |
|
|
2019
Q2 | $784K | Buy |
10,776
+107
| +1% | +$8.41K | 0.08% | 148 |
|
|
2019
Q1 | $860K | Sell |
10,669
-58
| -0.5% | -$4.75K | 0.1% | 130 |
|
|
2018
Q4 | $989K | Buy |
10,727
+6,216
| +138% | +$547K | 0.14% | 96 |
|
|
2018
Q3 | $426K | Buy |
4,511
+1,591
| +54% | +$151K | 0.12% | 94 |
|
|
2018
Q2 | $270K | Hold |
2,920
| – | – | 0.08% | 115 |
|
|
2018
Q1 | $276K | Sell |
2,920
-324
| -10% | -$35.6K | 0.09% | 121 |
|
|
2017
Q4 | $313K | Buy |
3,244
+324
| +11% | +$30.5K | 0.1% | 112 |
|
|
2017
Q3 | $259K | Hold |
2,920
| – | – | 0.09% | 127 |
|
|
2017
Q2 | $212K | Sell |
2,920
-200
| -6% | -$13.4K | 0.08% | 134 |
|
|
2017
Q1 | $203K | Buy |
+3,120
| New | +$196K | 0.08% | 142 |
|
Other funds holding ABBV
Northeast Financial Consultants's ABBV Position: Q2 2025 in Review
Northeast Financial Consultants held its AbbVie (ABBV) position steady in Q2 2025 at 16,867 shares worth $3.13M. The position accounts for 0.13% of the portfolio, ranked #86.
Northeast Financial Consultants first reported a position in ABBV in Q1 2017 and has held it in 34 quarters since. The position peaked at $3.53M in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.
- Northeast Financial Consultants held 16,867 shares of AbbVie worth $3.13M as of Q2 2025.
- Northeast Financial Consultants left its AbbVie share count unchanged in Q2 2025.
- AbbVie made up 0.13% of Northeast Financial Consultants's portfolio in Q2 2025, its #86 holding.
- Northeast Financial Consultants first reported a position in AbbVie in Q1 2017 and has held it in 34 quarters since.
- Northeast Financial Consultants's AbbVie position peaked at $3.53M in Q1 2025.
- 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.
Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.